In this week's InnovationRx newsletter, federal judges halt Trump's cuts to NIH research payments, rural hospitals' ongoing ...

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, ...

Novartis is buying Anthos Therapeutics from Blackstone’s drug development division, as it makes a bet on an experimental drug aimed at preventing strokes in patients with an irregular heart rhythm.

The acting chair of the, Mark Uyeda, took the first step Tuesday to rolling back a rule that would require thousands of ...

Certain hormonal contraceptives are associated with a higher stroke and heart attack risk, finds a large study from Denmark in The BMJ today that draws on prescription records to give more precise ...

Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots.

Health-care companies fell after disappointing earnings from one health insurer. Shares of Humana slid after the health-insurance firm warned of falling Medicare Advantage membership, and hinted that ...

MSN Laboratories Pvt. Ltd. urged the Federal Circuit to reconsider a three-judge panel’s January ruling that revived a patent for Novartis AG’s blockbuster heart-disease drug Entresto.

Novartis is buying Anthos Therapeutics from Blackstone’s drug development division, as it makes a bet on an experimental drug aimed at preventing strokes in patients with an irregular heart rhythm.

To boost its cardiovascular pipeline, Novartis has announced the acquisition of the company it co-founded with Blackstone ...

The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...